LBA7518-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

ConclusionsThe 18-mo FU confirms that durable RFS can be achieved with 2 cycles of neoadj IPI+NIVO without any additional adjuvant therapy. Pathologic response remains the strongest marker for RFS. TMB and IFN-y signature might serve as baseline markers identifying pts benefiting from neoadj IPI+NIVO. Neoadj 2 cycles IPI1+NIVO3 should be tested in a randomized phase III study versus adjuvant therapy.Clinical trial identificationNCT02977052.Legal entity responsible for the studyNetherlands Cancer Institute.FundingBMS.DisclosureE.A. Rozeman: Travel / Accommodation / Expenses: NanoString; Travel / Accommodation / Expenses: MSD. A.M. Menzies: Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre. O. Krijgsman: Research grant / Funding (institution): BMS. T.M. Van: Travel / Accommodation / Expenses: NanoString. A.C.J. van Akkooi: Advisory / Consultancy, Research grant / Funding (institution): Amgen; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: MSD-Merck; Advisory / Consultancy: Merck-Pfizer; Advisory / Consultancy: 4SC. R.A. Scolyer: Advisory / Consultancy: MSD; Advisory / Consultancy: Neracare; Advisory / Consultancy: Novartis. J. Hansson: Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: Novartis. G.V. Long: Advisory / Cons...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Abstract Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a ...
Source: Oncology (Williston Park, N.Y.) - Category: Cancer & Oncology Authors: Tags: Oncology (Williston Park) Source Type: research
Condition:   Melanoma Interventions:   Drug: Tavo;   Drug: Nivolumab;   Device: OncoSec Medical Electroporation Therapy System Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   OncoSec Medical Incorporated Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
kooi This review describes the progress that the concept of adjuvant therapies has undergone in the last 50 years and focuses on the most recent development where an adjuvant approach has been scientifically evaluated in melanoma clinical trials. Over the past decade the development of immunotherapies and targeted therapies has drastically changed the treatment of stage IV melanoma patients. These successes led to trials studying the same therapies in the adjuvant setting, in high risk resected stage III and IV melanoma patients. Adjuvant immune checkpoint blockade with anti-CTLA-4 antibody ipilimumab was the first dru...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Cancers, Vol. 12, Pages 1941: “To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers Cancers doi: 10.3390/cancers12071941 Authors: Mattia Garutti Silvia Buriolla Elisa Bertoli Maria Grazia Vitale Ernesto Rossi Giovanni Schinzari Alessandro Marco Minisini Fabio Puglisi Despite surgical resection and adjuvant therapies, stage III melanomas still have a substantial risk of relapse. Neoadjuvant therapy is an emerging strategy that might offer superior efficacy compared to adjuvant therapy. Moreover, neoadjuvant therapy has some virtual advantages: it might allow...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
AbstractPurpose of ReviewNeoadjuvant therapy in melanoma is an area of active investigation with numerous completed and ongoing trials studying a variety of therapeutic interventions utilizing diverse designs. Here, we review completed and ongoing neoadjuvant trials in melanoma, discuss endpoint assessment, and highlight biomarker development in this context.Recent FindingsHigh-risk resectable melanoma with clinically detectable lymph node (LN) with or without in-transit and/or satellite metastases represent ~  20% of melanoma patients and have a high risk of relapse despite definitive surgery. Adjuvant therapy with...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
ConclusionThe results showed high rates of objective response, RFS, and OS for patients undergoing immune profile-directed neoadjuvant immunotherapy for locally advanced melanoma. Furthermore, the study showed that treatment stratification based upon Tex frequency can potentially limit the adverse events associated with combination immunotherapy. These data merit further investigation with a larger validation study.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Hydrogen peroxide (H2O2) is a product of respiration in mitochondria and an important oxidizing agent in biological systems. Previous investigations have shown the efficacy of H2O2 in treating skin conditions suc...
Source: Journal of Otolaryngology - Head and Neck Surgery - Category: ENT & OMF Authors: Tags: Original research article Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Genetics | Grants | Legislation | Melanoma | Men | Merck | Nanotechnology | Neoadjuvant Therapy | Pfizer | Skin Cancer | Study | Toxicology | Yervoy